Couple iPSC-cardiomyocytes/cardiac fibroblasts with patient-derived organoids from CRC (β-catenin/NF-κB–high), HER2+ breast cancer (RTK crosstalk), and chondrosarcoma (cartilage ECM/MMP-rich, RANKL axis) in heart–tumor-on-a-chip microphysiology with controllable protease gradients to quantify EGCG ± NOAC (apixaban/rivaroxaban) effects on PAR-2–dependent inflammation, hypertrophy, fibrosis, invasion, and chemo-response. The gene discussed is ERBB2; the disease is breast carcinoma.